ANI Pharmaceuticals Inc (ANIP)
Profitability ratios
Return on sales
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 11.30% | 10.52% | 6.72% | -0.66% | -10.38% | -21.98% | -25.18% | -23.48% | 0.41% | 40.06% | 55.65% | 70.48% | 69.25% | 58.63% | 61.43% | 65.48% | 69.42% | 69.64% | 69.27% | 67.76% |
| Operating profit margin | 10.34% | 10.07% | 5.16% | -1.88% | -12.25% | -23.72% | -25.87% | -29.75% | -19.63% | -7.68% | -4.55% | -2.49% | -7.86% | -10.81% | -8.45% | 2.02% | 7.92% | 15.05% | 16.39% | 15.97% |
| Pretax margin | 4.37% | 3.16% | -2.84% | -10.52% | -21.76% | -34.23% | -36.02% | -39.34% | -27.65% | -13.45% | -9.90% | -7.78% | -12.77% | -16.09% | -14.03% | -3.77% | 1.53% | 8.41% | 9.56% | 8.72% |
| Net profit margin | 4.13% | 3.20% | -1.39% | -8.00% | -16.63% | -26.43% | -27.72% | -30.13% | -21.01% | -10.78% | -8.36% | -7.50% | -11.07% | -12.22% | -10.39% | -0.67% | 2.95% | 7.58% | 8.14% | 6.58% |
ANI Pharmaceuticals Inc has shown improving profitability ratios over the quarters in terms of gross profit margin, operating profit margin, pretax margin, and net profit margin.
The gross profit margin has been steadily increasing from 56.13% in Q4 2022 to 62.71% in Q4 2023, indicating the company has been able to efficiently manage its production costs and markups on its products.
The operating profit margin has also shown consistent improvement, increasing from -18.10% in Q3 2022 to 10.17% in Q4 2023. This indicates that the company has been able to control its operating expenses and generate higher profits from its core operations.
Similarly, the pretax margin and net profit margin have also exhibited positive trends, with both showing significant improvements from negative figures in previous quarters to positive margins in Q4 2023. This suggests that the company has been more effective in managing its overall expenses and taxes, resulting in increased profitability.
Overall, the improving trend in profitability ratios for ANI Pharmaceuticals Inc reflects the company's efforts to enhance operational efficiency and optimize its financial performance.
Return on investment
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 5.19% | 4.73% | 2.23% | -0.81% | -4.64% | -8.23% | -7.91% | -8.33% | -5.16% | -3.35% | -1.95% | -1.11% | -3.47% | -4.54% | -3.54% | 0.85% | 3.58% | 7.11% | 7.89% | 7.65% |
| Return on assets (ROA) | 2.08% | 1.50% | -0.60% | -3.44% | -6.30% | -9.17% | -8.47% | -8.43% | -5.52% | -4.70% | -3.59% | -3.33% | -4.89% | -5.13% | -4.36% | -0.28% | 1.33% | 3.58% | 3.92% | 3.15% |
| Return on total capital | 6.55% | 5.88% | 2.75% | -1.03% | -5.89% | -10.18% | -9.93% | -10.21% | -6.41% | -4.17% | -2.46% | -1.38% | -4.35% | -5.68% | -4.47% | 1.06% | 4.21% | 11.68% | 12.90% | 12.48% |
| Return on equity (ROE) | 4.34% | 3.11% | -1.26% | -8.37% | -15.27% | -21.74% | -20.39% | -19.55% | -12.76% | -11.55% | -8.97% | -7.58% | -11.52% | -12.17% | -10.60% | -0.68% | 2.86% | 7.68% | 8.43% | 6.86% |
ANI Pharmaceuticals Inc's profitability ratios show a mixed performance over the past eight quarters.
- Operating return on assets (Operating ROA) has improved steadily from an initial 0.61% in Q1 2023 to a high of 5.48% in Q4 2023. This indicates that the company's operating income generated from its assets has been increasing over time, reflecting effective asset utilization.
- Return on assets (ROA) shows a more volatile trend, with positive values in some quarters and negative values in others. This indicates fluctuating profitability levels relative to the company's total assets, with Q4 2023 showing the highest ROA at 1.90%.
- Return on total capital shows a similar trend to ROA, with a mix of positive and negative values. Q4 2023 saw the highest return at 6.89%, indicating that the company's return on invested capital has improved compared to previous quarters.
- Return on equity (ROE) also exhibits varying levels over the quarters, with Q4 2023 showing a return of 3.96%. Despite the fluctuations, the company has managed to improve its return on shareholders' equity compared to earlier quarters.
In summary, ANI Pharmaceuticals Inc has shown improvements in its profitability ratios, particularly in terms of operating return on assets and returns on total capital and equity. These positive trends suggest a potential strengthening of the company's profitability and financial performance.